Invega and Pregnancy
In previous animal studies involving Invega and pregnancy, the medicine increased the risk of newborn death. However, it is important to keep in mind that animals do not always respond to medicines in the same way that humans do. A healthcare may prescribe Invega to a pregnant woman if he or she believes that its benefits outweigh the possible risks to the unborn child.
Invega® (paliperidone) may not be safe for women who are pregnant. Animal studies of a similar medication showed an increased risk of newborn death.
The U.S. Food and Drug Administration (FDA) uses a pregnancy category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
When given to pregnant rats, risperidone (Risperdal®), which is closely related to Invega, increased the risk of death to the newborn animals.
However, it is important to note that animals do not always respond to medicines in the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the pregnant woman outweigh any possible risks to the unborn child.
If you are taking Invega and pregnancy occurs (or you are thinking of becoming pregnant), let your healthcare provider know. Your healthcare provider will consider both the benefits and risks of Invega during pregnancy before making a recommendation for your particular situation.